[Prevention of adverse effects in ribavirin and interferon combination therapy].
Izumi
Namiki
N
Department of Gastroenterology and Hepatology, Musashino Red-Cross Hospital.
D000014:Abnormalities, Drug-Induced / Q000209:etiology / Q000517:prevention & control; D000740:Anemia / Q000139:chemically induced* / Q000517:prevention & control*; D000818:Animals; D000998:Antiviral Agents / Q000009:adverse effects*; D002543:Cerebral Hemorrhage / Q000209:etiology / Q000517:prevention & control; D003875:Drug Eruptions / Q000209:etiology / Q000517:prevention & control; D004359:Drug Therapy, Combination; D001068:Feeding and Eating Disorders / Q000139:chemically induced / Q000517:prevention & control; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000009:adverse effects*; D012254:Ribavirin / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000633:toxicity; D014018:Tissue Distribution
D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons